早期子宫内膜癌伴脉管间隙浸润的辅助治疗:化疗是否有作用?
这项多机构回顾性队列研究纳入2005至2015年接受子宫切除术±淋巴结清扫的478例I–II期子宫内膜样癌伴LVSI患者,比较观察、放疗或化疗±放疗后的生存。结果显示辅助治疗较观察改善无进展生存,且3级肿瘤中化疗±放疗优于放疗或观察,但总生存无差异。
要点
- 早期EEC伴LVSI术后辅助治疗较观察改善PFS。
- 3级肿瘤中化疗±放疗的PFS优于放疗或观察。
- 辅助治疗未改善总生存。
核心结论
- 早期EEC伴LVSI术后辅助治疗较观察改善PFS,但总生存无差异。
- 3级EEC中辅助化疗±放疗较观察或单纯放疗改善PFS。
研究设计与样本
- 多机构回顾性队列研究,纳入2005至2015年接受子宫切除术±淋巴结清扫的I–II期EEC伴LVSI患者478例。
- 术后治疗分为观察143例(30%)、放疗232例(48.5%)、化疗±放疗103例(21.5%,其中95%接受放疗)。
- 中位年龄64岁,中位随访50.3个月。
主要发现
- 101例(21%)复发。
- 化疗±放疗组PFS优于观察(HR=0.18,95%CI:0.09-0.39),放疗组PFS优于观察(HR=0.31,95%CI:0.18-0.54),两种辅助治疗间无优劣。
- 3级肿瘤中化疗±放疗的PFS优于放疗(HR=0.25,95%CI:0.12-0.52)和观察(HR=0.10,95%CI:0.03-0.32)。
- 总生存按治疗分组无差异。
临床怎么用
- 早期EEC伴LVSI术后可考虑辅助治疗以改善PFS。
- 3级EEC伴LVSI可优先考虑辅助化疗±放疗。
局限性
- 回顾性设计,存在选择偏倚,观察组分期和分级较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Lymphovascular space invasion (LVSI) is an independent risk factor for recurrence and poor survival in early-stage endometrioid endometrial cancer (EEC), but optimal adjuvant treatment is unknown. We aimed to compare the survival of women with early-stage EEC with LVSI treated postoperatively with observation (OBS), radiation (RAD, external beam and/or vaginal brachytherapy), or chemotherapy (CHEMO)+/-RAD. METHODS: This was a multi-institutional, retrospective cohort study of women with stage I or II EEC with LVSI who underwent hysterectomy+/-lymphadenectomy from 2005 to 2015 and received OBS, RAD, or CHEMO+/-RAD postoperatively. Progression-free survival and overall survival were evaluated using Kaplan-Meier estimates and Cox proportional hazards models. RESULTS: In total, 478 women were included; median age was 64 years, median follow-up was 50.3 months. After surgery, 143 (30%) underwent OBS, 232 (48.5%) received RAD, and 103(21.5%) received CHEMO+/-RAD (95% of whom received RAD). Demographics were similar among groups, but those undergoing OBS had lower stage and grade. A total of 101 (21%) women recurred. Progression-free survival (PFS) was improved in both CHEMO+/-RAD (HR = 0.18, 95% CI: 0.09-0.39) and RAD (HR = 0.31, 95% CI: 0.18-0.54) groups compared to OBS, though neither adjuvant therapy was superior to the other. However, in grade 3 tumors, the CHEMO+/-RAD group had superior PFS compared to both RAD (HR 0.25; 95% CI: 0.12-0.52) and OBS cohorts (HR = 0.10, 95% CI: 0.03-0.32). Overall survival did not differ by treatment. CONCLUSIONS: In early-stage EEC with LVSI, adjuvant therapy improved PFS compared to observation alone. In those with grade 3 EEC, adjuvant chemotherapy with or without radiation improved PFS compared to observation or radiation alone.
引用
- Beavis AL, Yen TT, Stone RL, et al. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? Gynecol Oncol. 2020. PMID: 31948730. doi:10.1016/j.ygyno.2019.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。